R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed adenocarcinoma of the pancreas
• •Measurable metastatic disease No prior treatment for metastatic disease except immunotherapy (e.g., antibodies, vaccines, cytokines)
• •PATIENT CHARACTERISTICS:
• •Age: 18 and over
• •Performance status: ECOG 0-2
• •WBC at least 4,000/mm3 OR granulocyte count at least 1,500/mm3
• •Platelet count at least 100,000/mm3
• •Bilirubin no greater than 2.0 mg/dL
• •SGOT/SGPT no greater than 2 times normal
• •Creatinine no greater than 2.0 mg/dL OR creatinine clearance at least 50 mL/min
• •Not pregnant or nursing
• •Fertile patients must use effective contraception during and for 3 months after the study
• •No concurrent illness or active infection which would preclude study
• •No prior malignancy allowed unless disease free for the time period considered appropriate for cure of the specific cancer
• •No history of allergies to imidazole compounds (e.g., fluconazole, ketoconazole, miconazole, itraconazole, clotrimazole)
• •PRIOR CONCURRENT THERAPY:
• •No prophylactic filgrastim (G-CSF), sargramostim (GM-CSF), or thrombopoietin
• •Primary neoadjuvant or adjuvant chemotherapy allowed at least 6 months prior to detection of metastatic disease
• •Primary radiotherapy allowed at least 6 months prior to detection of metastatic disease
• •No concurrent use of proton pump inhibitors (e.g., omeprazole)